Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
about
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisBlood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
P2860
Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combination therapy of sodium- ...... etes: rationale and evidences.
@en
type
label
Combination therapy of sodium- ...... etes: rationale and evidences.
@en
prefLabel
Combination therapy of sodium- ...... etes: rationale and evidences.
@en
P2860
P1476
Combination therapy of sodium- ...... etes: rationale and evidences.
@en
P2093
Awadhesh Kumar Singh
Ritu Singh
P2860
P304
P356
10.1586/17512433.2016.1123616
P407
P577
2015-11-20T00:00:00Z